The Lp(a) drug trial known as HORIZON has revealed a significant disconnect between biological success and clinical outcomes, as the experimental drug pelacarsen failed to reduce heart attacks or strokes despite dramatically lowering target lipid levels. While the medication successfully hit its primary biochemical goal, it did not translate into a reduction of major cardiovascular events for The participants involved in the study.
Key Takeaways
- Biomarker Success, Clinical Failure: The drug pelacarsen significantly reduced levels of Lipoprotein(a), but failed to lower the incidence of heart attacks, strokes, or deaths.
- Long-term Observation: The HORIZON trial monitored participants for nearly five years to assess the impact of the drug on major cardiovascular events.
- Broad Risk Factor: Lipoprotein(a) is a genetic risk factor for cardiovascular disease that affects approximately 1 in 5 people worldwide.
- Scientific Uncertainty: The trial’s failure to meet clinical endpoints has left researchers questioning current cardiovascular treatment strategies and the reliance on surrogate markers.
- Novartis Involvement: The Phase 3 trial was funded by the pharmaceutical giant Novartis.
What Happened: The HORIZON Trial Results
Results from the Phase 3 HORIZON trial were presented on Saturday, November 7, 2026, at the American Heart Association’s scientific sessions and were published simultaneously in the New England Journal of Medicine. The study focused on the efficacy of pelacarsen, an experimental drug designed to target and reduce levels of Lipoprotein(a), or Lp(a).
According to the published findings, pelacarsen was highly effective at its intended biological task. It dramatically lowered the concentration of Lp(a)—a complex particle composed of lipids and proteins that, when present in high amounts, significantly heightens the risk of severe cardiovascular issues. However, the clinical reality was far less optimistic. In a randomized comparison between participants receiving the drug and those receiving a placebo, the trial showed no statistically significant difference in several critical health outcomes, including heart attacks, strokes, urgent coronary revascularization, or deaths.
The participants in the study were followed for nearly five years, providing a substantial window to observe whether the reduction in the Lp(a) marker would eventually lead to a reduction in actual medical emergencies. For the researchers involved, the lack of a clinical benefit despite the successful biological intervention has created a sense of profound confusion.
“This will leave a lot of people scratching their heads,” the trial leader stated, according to reporting by STAT.
Why It Matters: The Gap Between Markers and Medicine
The failure of the Lp(a) drug trial highlights a recurring and dangerous challenge in modern medicine: the gap between improving a biological marker and actually improving a patient’s life. In pharmaceutical research, a “surrogate endpoint” is a laboratory measurement (like blood pressure or cholesterol levels) used as a proxy for a clinical outcome (like a heart attack). While hitting a surrogate endpoint is a necessary step, it is not a guarantee of success.
This distinction is critical because Lp(a) is a major player in cardiovascular health. Unlike LDL cholesterol, which is heavily influenced by diet and lifestyle, Lp(a) levels are largely determined by genetics. Because it is a genetically driven risk factor, it has long been viewed as a prime target for novel therapies that could provide protection to the 20% of the population who carry high levels of the particle.
If lowering Lp(a) does not lead to fewer heart attacks, the medical community must grapple with several difficult questions:
- Is Lp(a) merely a bystander in the process of plaque formation?
- Is the current method of lowering it insufficient to change the course of the disease?
- Are other factors, such as inflammation or other lipid types, more critical to preventing strokes and heart attacks?
Deep-Dive: Understanding the Biology of Lp(a)
To understand why the Lp(a) drug trial results are so perplexing, one must first understand the unique nature of the particle itself. Lipoprotein(a) is often described as a “mashup” of lipids and proteins. It consists of a low-density lipoprotein (LDL)-like particle attached to a specific protein called apolipoprotein(a).
The Dual Threat of Lp(a)
Lp(a) is considered uniquely dangerous because it contributes to cardiovascular disease through two distinct mechanisms:
- Pro-atherogenic activity: Like LDL, Lp(a) carries cholesterol into the walls of the arteries, contributing to the buildup of plaque (atherosclerosis).
- Pro-thrombotic activity: The apolipoprotein(a) component is structurally similar to plasminogen, a protein that helps dissolve blood clots. This similarity can interfere with the body’s natural ability to break down clots, making the blood more prone to clotting and increasing the risk of a stroke or heart attack.
The HORIZON Trial Data Comparison
The following table summarizes the key clinical outcomes observed during the nearly five-year follow-up period of the HORIZON trial, comparing the pelacarsen group to the placebo group.
| Clinical Outcome | Pelacarsen Group Result | Placebo Group Result | Statistical Significance |
|---|---|---|---|
| Heart Attacks | No significant reduction | Baseline rate | None |
| Strokes | No significant reduction | Baseline rate | None |
| Urgent Coronary Revascularization | No significant reduction | Baseline rate | None |
| Deaths | No significant reduction | Baseline rate | None |
| Lp(a) Levels | Dramatic Reduction | No change | Highly Significant |
Note: Data based on findings presented at the American Heart Association’s scientific sessions and published in the New England Journal of Medicine.
Stakeholders and Reactions
The fallout from the trial affects a wide array of stakeholders, from the pharmaceutical companies investing billions into lipid research to the millions of patients living with high genetic risk.
The Pharmaceutical Industry
For Novartis, the sponsor of the trial, the results represent a significant setback in their cardiovascular pipeline. The failure of a Phase 3 trial—the final and most expensive stage of drug development—can have major implications for company valuation and future research directions. The biotech sector, which has seen a surge of interest in RNA-based therapies and antisense oligonucleotides designed to target Lp(a), may also see a period of increased skepticism.
The Medical Community
Cardiologists and lipidologists are now faced with a dilemma. For years, the scientific consensus has leaned toward the idea that lowering Lp(a) is a viable path to preventing cardiovascular disease. The HORIZON trial results suggest that this path may be more complex than previously thought. Some experts may argue that the drug’s mechanism of action is correct, but the intensity or duration of the reduction was not enough to overcome the existing damage in high-risk patients.
What It Means for You
If You Are a Patient
If you have been told by your doctor that you have high levels of Lipoprotein(a), it is important not to view these trial results as a reason to abandon preventative care. While the specific drug pelacarsen did not show clinical benefits in this trial, the science of Lp(a) is still evolving.
Currently, management of high Lp(a) typically focuses on controlling other modifiable risk factors, such as LDL cholesterol, blood pressure, and blood sugar. You should continue to follow your physician’s guidance regarding statins, lifestyle changes, and other prescribed medications. Do not attempt to self-treat or change your medical regimen based on recent clinical trial news.
If You Are an Investor
For those in the biotech and pharmaceutical sectors, the Lp(a) drug trial results serve as a cautionary tale regarding “biomarker-driven” drug development. Success in a Phase 2 trial that shows a reduction in a protein or enzyme does not always guarantee success in a Phase 3 trial that measures human lives. Investors should look closely at companies that have multiple pathways for addressing cardiovascular risk and those that are testing drugs against a broader range of clinical endpoints.
Counterpoints and Open Questions
While the trial’s primary conclusion is that pelacarsen failed to reduce clinical events, several scientific counterpoints and open questions remain that could change the interpretation of these results in the future.
Was the dose sufficient?
One possibility is that while pelacarsen lowered Lp(a) levels, it did not lower them enough or for a long enough period to halt the progression of existing arterial disease. Some researchers suggest that a much more aggressive reduction might be required to see a clinical benefit.
The role of existing plaque
The participants in the HORIZON trial were not necessarily starting from a clean slate. Many individuals with high Lp(a) may already have significant atherosclerotic buildup. It remains an open question whether lowering Lp(a) can reverse existing damage or if it is only effective as a primary prevention tool for those who have not yet developed significant plaque.
Other inflammatory pathwaysThere is a growing debate about whether cardiovascular disease is driven more by lipid levels or by systemic inflammation. If inflammation is the primary driver of the actual heart attack or stroke, then lowering the Lp(a) particle—even if it reduces the lipid load—might not be enough to stop the inflammatory cascade that leads to a clinical event.
What Happens Next
The scientific community will not stop investigating Lp(a). The failure of the HORIZON trial is likely to act as a catalyst for new research designs. Watch for the following developments:
- Newer Therapies: Other companies in the pipeline are testing different modalities, such as siRNA (small interfering RNA) therapies, which may offer more potent or sustained suppression of Lp(a).
- Combination Therapies: Researchers may look into whether combining Lp(a)-lowering drugs with anti-inflammatory medications or traditional statins produces a synergistic effect that single-target drugs lack.
- Refined Patient Selection: Future trials may attempt to identify a specific sub-group of patients—perhaps those with very high Lp(a) but low other risk factors—who might benefit more clearly from these interventions.
Frequently Asked Questions
What is Lipoprotein(a) (Lp(a))?
Lipoprotein(a) is a type of particle in your blood that carries cholesterol. Unlike standard LDL (often called “bad” cholesterol), Lp(a) levels are almost entirely determined by your genetics rather than your diet. High levels are a significant, independent risk factor for heart disease, heart attacks, and strokes because the particle is both cholesterol-rich and prone to promoting blood clots.
Why did the HORIZON trial fail if the drug worked on the Lp(a) levels?
In medical research, there is a difference between a “surrogate endpoint” and a “clinical endpoint.” The drug pelacarsen was successful at hitting the surrogate endpoint (lowering the Lp(a) level), but it failed to hit the clinical endpoint (preventing actual medical events like heart attacks). This means that while the drug changed the blood chemistry, that change was not enough to actually prevent the disease from progressing into a medical emergency in the study participants.
Can I test my Lp(a) levels?
Yes, Lp(a) can be measured through a standard blood test. Because it is genetically determined, most doctors recommend testing it at least once in a lifetime, especially if there is a family history of early heart disease. However, you should always discuss these results with a healthcare professional to understand what they mean for your specific risk profile.
Is there any way to lower Lp(a) naturally?
Currently, there is no strong evidence that lifestyle changes like diet or exercise can significantly lower Lp(a) levels, as they are primarily controlled by genetics. However, managing other risk factors—such as lowering your LDL cholesterol, managing blood pressure, and avoiding smoking—is still essential for reducing your overall cardiovascular risk.
As the medical community digests the findings from the HORIZON trial, the focus shifts from simply reducing a number on a lab report to finding the most effective way to prevent the life-threatening events that define cardiovascular disease
References
Featured image: Photo by Edward Jenner on Pexels
